Published: May 21, 2025

Background/Objectives: Amid rising global obesity rates and advances in weight-loss therapies, monitoring body composition ectopic fat could refine trial design. We quantified weight-related changes liver steatosis prior to widespread adoption of incretin treatments. Subjects/Methods: Adults (N=3,071) from the UK Biobank with repeat abdominal MRI scans were included. Percent weight change baseline was categorised: stable (0±2%), mild (2-5% gain/loss), moderate (5-10% or large (10-15% gain/loss). Intervention/Methods: data processed automatically two visits, spaced 2.7 years apart, derive volumetric visceral (VAT), subcutaneous adipose tissue (SAT), skeletal muscle volume (SM, indexed SM), infiltration (MFI_SM), psoas cross-sectional area (CSA) region. Liver content (LFC) assessed using LiverMultiScan. Dual-energy x-ray absorptiometry (DXA) measurements compared. Results: Weight gain occurred 28% all subjects (N=3071, age 63 years, male 49%, 13% obesity, 43% overweight). Moderate increased LFC, VAT, SAT, MFI_SM CSA (all p<.001). loss also 28%. Decreases observed loss: LFC -20% -33%, VAT -22 -38%, SAT -17 -30%, SM -3 -5%, SMI -4%, -4 respectively reduced loss, by -4%. For every 5% drop weight, there -16% reduction -11% -24% fat, -1.5% (or -1.4% SMI) -2.1% muscle, those overweight. DXA lean mass correlated weakly (rho 0.28-0.47). Conclusions: Using MRI, relative resulting can inform clinical trials, including placebo arm design power estimations.

Language: Английский